【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Those Medicines
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases?
2.2 Protein Kinases in Oncology
2.3 Mechanisms for Kinase Inhibition
2.4 Glossary of Terms
3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024
3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013
3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013
3.1.2 Leading Companies in the Protein Kinase Inhibitor Market
3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024
3.2.1 Changing Market Shares by Segment 2014-2024
3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024
3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013
3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024
3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market
3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024
4. Leading National and Regional Markets, 2014-2024
4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer
4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change Through to 2024?
4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.4 The US Market: Drivers and Restraints, 2014-2024
4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024
4.5.1 EU Market: Drivers and Restraints
4.5.2 German Market Forecast, 2014-2024
4.5.3 French Market Forecast, 2014-2024
4.5.4 Italian Market Forecast, 2014-2024
4.5.5 UK Market Forecast, 2014-2024
4.5.6 Spanish Market Forecast, 2014-2024
4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024
4.7.1 Chinese Market Forecast, 2014-2024
4.7.2 Brazilian Market Forecast, 2014-2024
4.7.3 Russian Market Forecast, 2014-2024
4.7.4 Indian Market Forecast, 2014-2024
5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia
5.1.1 Gleevec (imatinib) – Novartis
5.1.1.1 Historic Sales Performance
5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna
5.1.1.3 Gleevec Forecast, 2014-2024
5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb
5.1.2.1 Patents and Market Exclusivity
5.1.2.2 Historic Sales Performance
5.1.2.3 Sprycel Forecast, 2014-2024
5.1.3 Tasigna (nilotinib) – Novartis
5.1.3.1 Indications and Market Exclusivity
5.1.3.2 Historic Sales Performance
5.1.3.3 Tasigna Forecast, 2014-2024
5.1.4 Bosulif (bosutinib) – Pfizer
5.1.4.1 Bosulif Forecast, 2014-2024
5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
5.1.5.1 Iclusig Forecast, 2014-2024
5.2 EGFR Inhibitors
5.2.1 Tarceva (erlotinib) – Roche/Astellas
5.2.1.1 Patent Litigation and Market Exclusivity
5.2.1.2 Historic Sales Performance, 2004-2012
5.2.1.3 Tarceva Forecast, 2014-2024
5.2.2 Iressa (gefitinib) – AstraZeneca
5.2.2.1 Historic Sales Performance, 2003-2012
5.2.2.2 Iressa Forecast, 2014-2024
5.2.3 Gilotrif (afatinib) – Boehringer Ingelheim
5.2.3.1 Gilotrif Forecast, 2014-2024
5.3 Angiogenesis Inhibitors
5.3.1 Nexavar (sorafenib) – Bayer/Onyx
5.3.1.1 Historic Sales Performance, 2006-2012
5.3.1.2 Nexavar Forecast, 2014-2024
5.3.2 Sutent (sunitinib) – Pfizer
5.3.2.1 Historic Sales Performance, 2006-2012
5.3.2.2 Sutent Forecast, 2014-2024
5.3.3 Votrient (pazopanib) – GSK
5.3.3.1 Historic Sales Performance, 2010-2012
5.3.3.2 Votrient Forecast, 2014-2024
5.3.4 Inlyta (axitinib) – Pfizer
5.3.4.1 Inlyta Forecast, 2014-2024
5.4 BRAF and MEK Inhibitors
5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo
5.4.1.1 Zelboraf Forecast, 2014-2024
5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – GSK
5.4.2.1 Mekinist Forecast, 2014-2024
5.4.2.2 Tafinlar Forecast, 2014-2024
5.5 mTOR Inhibitors
5.5.1 Afinitor (everolimus) – Novartis
5.5.1.1 Patents and Market Exclusivity
5.5.1.2 Historic Sales Performance
5.5.1.3 Afinitor Forecast, 2014-2024
5.5.2 Torisel (temsirolimus) – Pfizer
5.5.2.1 Torisel Forecast, 2014-2024
5.6 Other leading Anticancer Kinase Inhibitors
5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics
5.6.1.1 Imbruvica Forecast, 2014-2024
5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte
5.6.2.1 Jakafi Forecast, 2014-2024
5.6.3 Xalkori (crizotinib) – Pfizer
5.6.3.1 Xalkori Forecast, 2014-2024
5.6.4 Cometriq (cabozantinib) – Exelixis
5.6.4.1 Cometriq Forecast, 2014-2024
5.6.5 Caprelsa (vandetanib) – AstraZeneca
5.6.5.1 Caprelsa Forecast, 2014-2024
5.6.6 Tykerb (lapatinib) – GSK
5.6.6.1 Historic Sales Performance, 2007-2012
5.6.6.2 Tykerb Forecast, 2014-2024
5.6.7 Stivarga (regorafenib) – Bayer
5.6.7.1 Stivarga Forecast, 2014-2024
6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2014-2024
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 Palbociclib – Pfizer
6.1.1.1 Palbociclib Forecast, 2014-2024
6.1.2 LEE-011 – Novartis
6.1.2.1 LEE-011 Forecast, 2014-2024
6.1.3 Bemaciclib (LY2835219) – Eli Lilly
6.1.3.1 Bemaciclib Forecast, 2014-2024
6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development
6.2.1 Alectinib – Roche
6.2.1.1 Alectinib Forecast, 2014-2024
6.2.2 Ceritinib (LDK378) – Novartis
6.2.2.1 Ceritinib Forecast, 2014-2024
6.2.3 AP26113 – ARIAD
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Idelalisib – Gilead
6.3.1.1 Idelalisib Forecast, 2014-2024
6.3.2 RG7601 (ABT-199) – Roche/AbbVie
6.3.2.1 ABT-199 Sales Forecast, 2014-2024
6.3.3 IPI-145 – Infinity Pharmaceuticals
6.3.3.1 IPI-145 Forecast, 2014-2024
6.3.4 Buparlisib (BKM120) – Novartis
6.3.4.1 Buparlisib Forecast, 2014-2024
6.3.5 ONO-4059 – Ono Pharmaceuticals
6.3.6 Copanlisib (BAY 80-6946) – Bayer
6.3.7 Pictilisib (GDC-0941) – Roche
6.3.8 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973) – Roche
6.4.1.1 Cobimetinib Forecast, 2014-2024
6.4.2 Encorafenib (LGX818) – Novartis
6.4.3 Binimetinib (MEK162) – Novartis
6.4.4 Selumetinib (AZD 6244) – AstraZeneca
6.5 Other Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.1.1 Volasertib Forecast, 2014-2024
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo
6.5.4 Dovotinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 CO-1686 – Clovis Oncology
7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market
7.2 Strengths
7.2.1 Oral Dosage Preferred Over Injection
7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits
7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated
7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth
7.3 Weaknesses
7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition
7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action
7.3.3 Monoclonal Antibodies are More Specific than Small Molecules
7.4 Opportunities
7.4.1 Novel Targets Identified Through Cancer Genomics
7.4.2 Combination Therapies Bring Additive Benefits
7.4.3 Commercial Success Leveraged by Clinical Benefit
7.5 Threats
7.5.1 Small Molecules Generics Are Easy to Produce
7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded
7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market
7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.7.1 Rivalry Among Competitors
7.7.2 Threat of New Entrants
7.7.3 Power of Suppliers
7.7.4 Power of Buyers
7.7.5 Threat of Substitutes
8. Research Interview
8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
8.1.2 Combining Therapies Offers Significant Benefit to Patients
8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers
9. Conclusions
9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024
9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth
9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024
【レポート販売概要】
■ タイトル：世界の癌治療用キナーゼ阻害剤市場：Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など■ 英文：Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
■ 発行日：2014年6月
■ 調査会社：visiongain
■ 商品コード：VISG409052
■ 調査対象地域：グローバル
- Marquee Energy Ltd.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Marquee Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Marquee Energy Ltd. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
- 世界の不妊症治療薬パイプライン分析The market for reproductive medicine is experiencing a paradigm shift with new latest techniques being used and awareness among people increasing due to imparting knowledge about these techniques. The infertility drugs market promises significant room for growth. The market has high potential to scale up in order to meet the needs of infertile couples and also due to growth in reproductive tourism …
- ConocoPhillips：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013ConocoPhillips Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary ConocoPhillips Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key opera …
- Comprehensive MVNO/MVNE PackageThis package is simply the most comprehensive package available in the market. It includes a real MVNO Business Plan from an actual launch plan. It includes a complete pre-paid MVNO business plan with information to support planning needs while easy to modify to reflect different strategies. It also includes a fully functional MVNO Business Plan Spreadsheet (in Excel) enabling financial forecastin …
- EVP-6124 (Alzheimer’s Disease)：市場予測と分析（～2022）EVP-6124 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “EVP-6124 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies ar …
- 世界の自動車排出ガス規制および影響分析The automotive exhaust aftertreatment systems market is estimated to be 141,366.05 Thousand units in 2015, and is projected to reach 206,430.48 thousand units by 2020, growing at a CAGR of 7.87% during the forecast period. The automotive exhaust aftertreatment systems market has witnessed considerable growth in countries such as the U.S., China, India, and Mexico, owing to progressively stringent …
- 肺線維症(Pulmonary Fibrosis)の治療薬パイプライン動向（2015年上半期版）Pulmonary Fibrosis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H1 2015’, provides an overview of the Pulmonary Fibrosis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mecha …
- 世界のCNGタンク/シリンダー市場2015The Global CNG Tank/Cylinder Industry 2015 Market Research Report is a professional and in-depth study on the current state of the CNG Tank/Cylinder industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The CNG Tank/Cylinder market analysis is provided for the international markets including development tren …
- Botas Petroleum Pipeline Corporation：石油・ガスバリューチェーン分析レポート2013Botas Petroleum Pipeline Corporation Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Botas Petroleum Pipeline Corporation" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Botas Petroleum Pipeline Corporation”. The report provides key information relating to oil and gas assets of the company along with its op …
- 美白歯磨き製品の世界市場：美白歯磨き粉、ホワイトニングテープAbout Teeth Whitening Teeth whitening is a bleaching process that has gained popularity over the past two decades. It essentially refers to the process of removing stains or treating discolorations using chemicals, of which carbamide peroxide and hydrogen peroxide being the most common. The concept of teeth whitening has evolved from being a treatment for trauma-related teeth discoloration to a co …
- フォトニックセンサの世界市場：光ファイバーセンサ、バイオフォトニックセンサ、イメージセンサAbout Photonic Sensor The use of light as an instrument of precision creates numerous opportunities for sensing technology and analytics. Photonic sensors are devices that have the capability to sense light and release electrical pulses. Since their introduction, the devices have evolved continuously and are being used in several industries. The use of photonic sensing technology has the following …
- モバイルウォレットの世界市場2016-2020About Mobile Wallets Mobile wallets are electronic money accounts that can be maintained and used via cell phones and other mobile devices. These wallets help account holders pay bills or purchase goods online. Often, companies give offers and discounts to encourage customers to use these apps. Mobile wallets are based on technologies, such as near-field communication (NFC), and have revolutionize …
- フォトマスク（Photomask）の世界市場About Photomasks Photomasks are high-purity quartz or glass plates, which contain pattern of ICs. Photomasks are used in the reproduction of pattern structures for the manufacture of electronic circuits, printed circuit boards and LCD displays, and for the serial production of reticles and other microstructures. Photomasks are used at wavelengths of 365 nm, 248 nm, and 193 nm. ICs are manufactured …
- 非鉄金属鋳物の世界市場：アルミニウム鋳物、銅鋳物、亜鉛鋳物、マグネシウム鋳物About Non-ferrous Casting Metal casting is a manufacturing process in which metal (molten or liquid) is poured into a mold made of sand or ceramic plaster. The mold contains a hollow cavity of the desired shape, to form geometrically complex parts. The most common non-ferrous metals used for casting are aluminum, magnesium, zinc, and copper-based alloys. Metal casting finds application in vehicles …
- STaaS（Storage-as-a-Service）の世界市場About Storage-as-a-Service (STaaS) Storage-as-a-service (STaaS) is a business model in which the service provider leases its storage infrastructure to an enterprise for storing its business data subsequent to establishing an SLA with them. This data can be actual backup or archive data. STaaS is one among many cloud storage service offerings currently being utilized by various enterprises worldwid …
